Systematic evaluation of the efficacy and safety of intravenous human immunoglobulin combined with cyclophosphamide in the treatment of systemic lupus erythematosus
|更新时间:2025-09-26
|
Systematic evaluation of the efficacy and safety of intravenous human immunoglobulin combined with cyclophosphamide in the treatment of systemic lupus erythematosus
ZHANG Junke,HAO Jie,ZHANG Yi,et al.Systematic evaluation of the efficacy and safety of intravenous human immunoglobulin combined with cyclophosphamide in the treatment of systemic lupus erythematosus[J].ZHONGGUO YAOFANG,2023,34(19):2396-2401.
ZHANG Junke,HAO Jie,ZHANG Yi,et al.Systematic evaluation of the efficacy and safety of intravenous human immunoglobulin combined with cyclophosphamide in the treatment of systemic lupus erythematosus[J].ZHONGGUO YAOFANG,2023,34(19):2396-2401. DOI: 10.6039/j.issn.1001-0408.2023.19.16.
Systematic evaluation of the efficacy and safety of intravenous human immunoglobulin combined with cyclophosphamide in the treatment of systemic lupus erythematosus
To systematically evaluate the safety and effectiveness of intravenous human immunoglobulin (IVIG) combined with cyclophosphamide in the treatment of systemic lupus erythematosus (SLE), and to provide an evidence-based basis for clinical medication.
METHODS
2
Retrieved from PubMed, Embase, Cochrane Library, CBM, CNKI and Wanfang database, randomized controlled trials (RCTs) about IVIG combined with cyclophosphamide versus cyclophosphamide alone based on glucocorticoids were collected. The quality of the included literature was evaluated with Cochrane 5.1.0 risk of bias assessment tool after literature screening and data extraction, and meta-analysis was performed by using RevMan 5.4 software.
RESULTS
2
A total of 13 RCTs were included, involving 842 patients. Meta-analysis showed that compared with cyclophosphamide alone, IVIG combined with cyclophosphamide improved the overall response rate of systemic lupus erythematosus [RR=1.23, 95%CI(1.15,1.32),
P
<0.000 01
]
, lowered the systemic lupus e
rythematosus disease activity index [MD=-2.05, 95%CI(-2.51, -1.60),
P
<0.000 01
]
, relieved 24 h proteinuria [MD=-1.29, 95%CI(-1.57, -1.01),
P
<0.000 01
]
, reduced the inflammatory factor MCP-4 [MD=-28.04, 95%CI(-32.72, -23.37,
P
<0.000 01)
]
, IL-4 [MD=-1.66, 95%CI(-1.96, -1.36),
P
<0.000 01
]
, and boosted immune complement C3 [SMD=0.74,95%CI(0.34,1.14),
P
=0.000 3
]
and complement C4 [SMD=0.99,95%CI(0.31,1.67),
P
=0.004
]
; it had similar incidence of adverse drug reactions to cyclophosphamide therapy alone [RR=0.81, 95%CI(0.57, 1.17),
P
=0.26
]
.
CONCLUSIONS
2
Compared with cyclophosphamide alone, IVIG combined with cyclophosphamide has a positive role in improving the overall response rate of treating SLE, improving clinical symptoms, reducing inflammatory factors, improving immune function, but the results should be interpreted with caution.
Chinese Rheumatology Association . 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus [J ] . Chin J Intern Med , 2020 , 59 ( 3 ): 172 - 185 .
DURCAN L , O’DWYER T , PETRI M . Management strategies and future directions for systemic lupus erythematosus in adults [J ] . Lancet , 2019 , 393 ( 10188 ): 2332 - 2343 .
FAVA A , PETRI M . Systemic lupus erythematosus:diagnosis and clinical management [J ] . J Autoimmun , 2019 , 96 : 1 - 13 .
PALMER S C , TUNNICLIFFE D J , SINGH-GREWAL D , et al . Induction and maintenance immunosuppression treatment of proliferative lupus nephritis:a network meta-analysis of randomized trials [J ] . Am J Kidney Dis , 2017 , 70 ( 3 ): 324 - 336 .
RÜTTER A , LUGER T A . High-dose intravenous immunoglobulins:an approach to treat severe immune-mediated and autoimmune diseases of the skin [J ] . J Am Acad Dermatol , 2001 , 44 ( 6 ): 1010 - 1024 .
CORVETTA A , DELLA BITTA R , GABRIELLI A , et al . Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus:report of three cases [J ] . Clin Exp Rheumatol , 1989 , 7 ( 3 ): 295 - 299 .
HUNDT M , MANGER K , DÖRNER T , et al . Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin [J ] . Rheumatology , 2000 , 39 ( 11 ): 1301 - 1302 .
KARIM M Y , PISONI C N , KHAMASHTA M A . Update on immunotherapy for systemic lupus erythematosus:what’s hot and what’s not [J ] . Rheumatology , 2009 , 48 ( 4 ): 332 - 341 .
WINDER A , MOLAD Y , OSTFELD I , et al . Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin:report of 2 cases [J ] . J Rheumatol , 1993 , 20 ( 3 ): 495 - 498 .
PETRI M , ORBAI A M , ALARCÓN G S , et al . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus [J ] . Arthritis Rheum , 2012 , 64 ( 8 ): 2677 - 2686 .
LIU K F , YANG Y J , ZHANG X J , et al . Meta-analysis of efficacy and safety of intranasal administration of dexmedetomidine versus oral administration of chloral hydrate for programmed sedation in children [J ] . China Pharm , 2020 , 31 ( 4 ): 484 - 489 .
LIU K F , ZHANG Y Y , YANG L , et al . Meta-analysis of the effectiveness and safety of low-molecular-weight heparin combined with progesterone in the treatment of repeated implant failure in embryo transfer patients [J ] . China Pharm , 2020 , 31 ( 23 ): 2895 - 2901 .
ZHOU S M . Clinical efficacy evaluation of cyclophosphamide combined with immunoglobulin in the treatment of systemic lupus erythematosus [J ] . Mod Diagn Treat , 2013 , 24 ( 6 ): 1312 - 1313 .
JIN J . Effects of cyclophosphamide combined with human immunoglobulin on inflammatory factors and immune function in patients with systemic lupus erythematosus [J ] . Contemp Med , 2021 , 27 ( 24 ): 62 - 64 .
YANG H J , LI ZH , HAN Y , et al . Clinical effect of cyclophosphamide plus human immunoglobulin for systemic lupus erythematosus [J ] . Prog Mod Biomed , 2016 , 16 ( 5 ): 933 - 935 .
GAO D W . Curative effect of cyclophosphamide combined with human immunoglobulin in the treatment of systemic lupus erythematosus and its impact on serum MCP-4 and IL-4 in patients [J ] . China Prac Med , 2017 , 12 ( 13 ): 81 - 83 .
YU J , MA L . Study on cyclophosphamide combined with human immunoglobulin in the treatment of systemic lupus erythematosus and its effect on the serum levels of MCP-4 and IL-4 [J ] . Hainan Med J , 2015 , 26 ( 2 ): 175 - 177 .
BI D Y , ZHANG H , ZHENG H M , et al . Efficacy and safety of cyclophosphamide combined with human immunoglobulin in treatment of elderly patients with SLE [J ] . China J Mod Med , 2018 , 28 ( 5 ): 103 - 105 .
HU X P . Analysis of curative effect of cyclophosphamide combined with human immunoglobulin in the treatment of SLE [J ] . China Continuing Med Edu , 2017 , 9 ( 3 ): 161 - 163 .
MO Y , JIANG X Y , CHEN S M , et al . High dose intravenous immunoglobulins to treat children’s systemic lupus erythematosus [J ] . Chin J Rheumatol , 2001 , 5 ( 2 ), 110 - 112 .
DENG X J , LI R Z , HUANG J P . Different doses of intravenous immunoglobulin were administered as adjuvant therapy clinical observation of lupus nephritis [J ] . Clin Med , 2003 , 23 ( 10 ): 50 - 51 .
BOLETIS J N , IOANNIDIS J P , BOKI K A , et al . Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [J ] . Lancet , 1999 , 354 ( 9178 ): 569 - 570 .
ZHENG C , DENG M . Clinical observation of large dose gammaglobulin adjuvant in patients with severe systemic infection lupus erythematosus [J ] . Pract Clin J Integrat Tradit Chin West Med , 2003 , 3 ( 5 ): 34 .
FEI Y Y , SHI X C , GAN F Y , et al . Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years [J ] . Clin Rheumatol , 2014 , 33 ( 1 ): 57 - 63 .
FORTUNA G , BRENNAN M T . Systemic lupus erythematosus:epidemiology,pathophysiology,manifestations,and management [J ] . Dent Clin North Am , 2013 , 57 ( 4 ): 631 - 655 .
BASTA M . Modulation of complement-mediated immune damage by intravenous immune globulin [J ] . Clin Exp Immunol , 1996 , 104 ( Suppl 1 ): 21 - 25 .
Chinese Rheumatology Association . Guidelines for diagnosis and treatment of systemic lupus erythematosus [J ] . Chin J Rheumat , 2010 , 14 ( 5 ): 342 - 346 .
HO A , BARR S G , MAGDER L S , et al . A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus [J ] . Arthritis Rheum , 2001 , 44 ( 10 ): 2350 - 2357 .
Systematic review and meta-analysis of health state utility for global patients with hemophilia
Immune checkpoint inhibitors combined with neoadjuvant chemotherapy and adjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer: a meta-analysis
Meta-analysis of the efficacy and safety of apatinib combined with PD-1/PD-L1 inhibitors in the treatment of malignant solid tumors
Meta-analysis of the efficacy of dydrogesterone combined with estradiol valerate for the prevention of intrauterine adhesion and prognosis improvement after induced abortion
Risk factors of ineffective eradication therapy of adult Helicobacter pylori infection: a meta-analysis
Related Author
FANG Yunhai
SHI Zhao
FENG Junchao
LI Shunping
YANG Chunyan
ZHANG Shaohua
LI Rongkang
PENG Lei
Related Institution
Shandong Haemophilia Treatment Center, Shandong Blood Center
Center for Health Preference Research, Shandong University
NHC Key Lab of Health Economics and Policy Research (Shandong University)
Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University
Dept. of Urology, the Second Hospital of Lanzhou University